Safety Study of Adjuvant Vaccine to Treat Melanoma Patients
NCT01079741
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
34
Enrollment
OTHER
Sponsor class
Conditions
Melanoma
Interventions
BIOLOGICAL:
NY-ESO-1 protein; Poly-ICLC; Montanide
Sponsor
Nina Bhardwaj
Collaborators
[object Object]
[object Object]
[object Object]